Les données mises à jour de l‘essai de phase 1 du traitement oral IDHIFA® (enasidenib) montrent des réponses cliniques durables chez les patients atteints d’une leucémie aiguë myéloïde en rechute ou réfractaire avec mutation IDH2
To view full article click here
Fact Checked & Editorial Guidelines
Our Fact Checking Process
We prioritize accuracy and integrity in our content. Here's how we maintain high standards:
- Expert Review: All articles are reviewed by subject matter experts.
- Source Validation: Information is backed by credible, up-to-date sources.
- Transparency: We clearly cite references and disclose potential conflicts.
Reviewed by: Subject Matter Experts
Our Review Board
Our content is carefully reviewed by experienced professionals to ensure accuracy and relevance.
- Qualified Experts: Each article is assessed by specialists with field-specific knowledge.
- Up-to-date Insights: We incorporate the latest research, trends, and standards.
- Commitment to Quality: Reviewers ensure clarity, correctness, and completeness.
Look for the expert-reviewed label to read content you can trust.
LMF green
Mente e denaro
LMF crypto
Sala Stampa